The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Abstract
A mutated cyclin-dependent kinase 4 (CDK4) was identified as a tumor-specific antigen recognized by HLA-A2. 1-restricted autologous cytolytic T lymphocytes (CTLs) in a human melanoma. The mutated CDK4 allele was present in autologous cultured melanoma cells and metastasis tissue, but not in the patient's lymphocytes. The mutation, an arginine-to-cysteine exchange at residue 24, was part of the CDK4 peptide recognized by CTLs and prevented binding of the CDK4 inhibitor p16 INK4a , but not of p21 or of p27 KIP1 . The same mutation was found in one additional melanoma among 28 melanomas analyzed. These results suggest that mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16 INK4a .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Self-citationA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Polyak, K., Lee, M.-H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21
Toyoshima, H., & Hunter, T. (1994) · Cell · doi:10.1016/0092-8674(94)90573-8 · Cited by 2,043
A role for sunlight in skin-cancer – UV-induced p53 mutations in squamous-cell carcinoma
Brash, D. E., Rudolph, J. A., Simon, J. A., Lin, A., McKenna, G. J., Baden, H. P., Halperin, A. J., & Pontén, J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.10124 · Cited by 1,959
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351
Immunity to Methylcholanthrene-Induced Sarcomas
(1957) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/18.6.769 · Cited by 1,229
Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,136
Germline p16 mutations in familial melanoma
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 977
Brichard, V, Van Pel, A., Wölfel, T., Wölfel, C., De Plaen, E., Lethé, B., Coulie, P., & Boon, T. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.2.489 · Cited by 950
Self-citationCoulie, P. G., Brichard, V, Van Pel, A., Wölfel, T., Schneider, J., Traversari, C., Mattei, S., De Plaen, E., Lurquin, C., Szikora, J. P., et al. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.35 · Cited by 903
Self-citationRetinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J. (1995) · Nature · doi:10.1038/375503a0 · Cited by 899
Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897
Feltkamp, M. C. W., Smits, H. L., Vierboom, M. P. M., Minnaar, R. P., De Jongh, B. M., Drijfhout, J. W., Schegget, J. T., Melief, C. J. M., & Kast, W. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230929 · Cited by 825
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit
Gu, Y., Turck, C. W., & Morgan, D. O. (1993) · Nature · doi:10.1038/366707a0 · Cited by 764
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules
Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., & Sette, A. (1993) · Cell · doi:10.1016/0092-8674(93)90472-3 · Cited by 628
Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
Salter, R. D., Howell, D. N., & Cresswell, P. (1985) · Immunogenetics · doi:10.1007/bf00375376 · Cited by 566
Mutations and altered expression of p16INK4 in human cancer.
Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., & Beach, D. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11045 · Cited by 539
Self-citationTumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
Koh, J., Enders, G. H., David Dynlacht, B., & Harlow, E. (1995) · Nature · doi:10.1038/375506a0 · Cited by 516
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 508
Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes
Wölfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Zum Büschenfelde, K. M., & Boon, T. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240340 · Cited by 411
Self-citationDeletion of p16 and p15 genes in brain tumors.
Jen, J., Harper, J. W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S. D., Willson, J. K. V., Kinzler, K. W., & Vogelstein, B. (1994) · PubMed · Cited by 404
Inhibition of Ras-Induced Proliferation and Cellular Transformation by p16 INK4
Serrano, M., Gómez-Lahoz, E., DePinho, R. A., Beach, D., & Bar-Sagi, D. (1995) · Science · doi:10.1126/science.7809631 · Cited by 373
Self-citationCoamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.
Khatib, Z. A., Matsushime, H., Valentine, M. B., Shapiro, D. N., Sherr, C. J., & Look, A. T. (1993) · PubMed · Cited by 338
Mori, T., Miura, K., Aoki, T., Nishihira, T., Mori, S., & Nakamura, Y. (1994) · PubMed · Cited by 333
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J., & Melief, C. J. M. (1989) · Cell · doi:10.1016/0092-8674(89)90006-8 · Cited by 301
Van den Eynde, B., Lethé, B., Van Pel, A., De Plaen, E., & Boon, T. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.6.1373 · Cited by 298
Self-citationHebert, J., Cayuela, J., Berkeley, J., & Sigaux, F. (1994) · Blood · doi:10.1182/blood.v84.12.4038.bloodjournal84124038 · Cited by 281
Mutations associated with familial melanoma impair p16INK4 function
Ranade, K., Hussussian, C. J., Sikorski, R. S., Varmus, H. E., Goldstein, A. M., Tucker, M. A., Serrano, M., Hannon, G. J., Beach, D., & Dracopoli, N. C. (1995) · Nature Genetics · doi:10.1038/ng0595-114 · Cited by 280
Self-citationCTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., & Eisenbach, L. (1994) · Nature · doi:10.1038/369067a0 · Cited by 254
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
He, J., Allen, J. R., Collins, V. P., Allalunis‐Turner, M. J., Godbout, R., Day, R. S., & James, C. D. (1994) · PubMed · Cited by 238
Knuth, A., Danowski, B., Oettgen, H. F., & Old, L. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.11.3511 · Cited by 236
Mutation and altered expression of p16^ in human cancer
Okamoto, A. (1994) · Proceedings of the National Academy of Sciences · Cited by 234
Nijman, H. W., Houbiers, J. G. A., Vierboom, M. P. M., van der Burg, S. H., Drijfhout, J. W., D'Amaro, J., Kenemans, P., Melief, C. J. M., & Kast, W. M. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230603 · Cited by 193
Pardoll, D. M. (1994) · Nature · doi:10.1038/369357a0 · Cited by 150
Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M., & Nakamura, Y. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2090 · Cited by 117
Uenaka, A., Ono, T., Akisawa, T., Wada, H., Yasuda, T., & Nakayama, E. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.5.1599 · Cited by 91
5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors.
Srivastava, P. K., Chen, Y., & Old, L. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.11.3807 · Cited by 66
Bergeyck, V. D., Plaen, E. D., Chomez, P., Boon, T., & Pel, A. V. (1994) · European Journal of Immunology · doi:10.1002/eji.1830240941 · Cited by 38
Sequence analysis of DNA from formalin‐fixed, paraffin‐embedded human malignant melanoma
Volkenandt, M., McNutt, N. S., & Albino, A. P. (1991) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.1991.tb00155.x · Cited by 24
Tum—mutation P35B generates the MHC-binding site of a new antigenic peptide
Szikora, J., Pel, A. V., & Boon, T. (1993) · Immunogenetics · doi:10.1007/bf00216837 · Cited by 19
Cited by
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
A Genome-Wide Transcriptional Analysis of the Mitotic Cell Cycle
Cho, R. J., Campbell, M. J., Winzeler, E. A., Steinmetz, L., Conway, A., Wodicka, L., Wolfsberg, T. G., Gabrielian, A. E., Landsman, D., Lockhart, D. J., et al. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80114-8 · Cited by 2,046
Metadata
- Authors
- Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D.
- Venue
- Science
- Published
- 1995-09
- Volume
- 269
- Issue
- 5228
- Pages
- 1281-1284
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2052912081
- Cited by
- 1,154
- References
- 48
- FWCI
- 25.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.